Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that alters the unfolded protein response (UPR) through selective GRP78 inhibition and induces reactive oxygen species (ROS) which causes DNA damage and cell cycle arrest.
Lead Product(s): Encoberminogene Rezmadenovec,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: BOLD-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition.
Lead Product(s): Encoberminogene Rezmadenovec,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: BOLD-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
Preclinical experiments have repeatedly shown that BOLD-100 improves outcomes in combination with a wide range of existing anti-cancer therapies, with particular synergy evident in drug-resistant cell lines.
Lead Product(s): BOLD-100,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: BOLD-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hana Pharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 13, 2022
Details:
BOLD-100, a first-in-class anti-resistance oncology therapeutic, has demonstrated potent anti-tumor activity in combination with a PD-1 checkpoint inhibitor in a validated I/O in vivo model of colorectal cancer.
Lead Product(s): BOLD-100,Pembrolizumab
Therapeutic Area: Oncology Product Name: BOLD-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021
Details:
BOLD-100-001 is an open-label, multicenter two-stage study designed to evaluate the safety and efficacy of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastric, pancreatic, colorectal and bile duct cancers.
Lead Product(s): BOLD-100,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: BOLD-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2021
Details:
BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition; and (2) induces reactive oxygen species (ROS) which causes DNA damage and cell cycle arrest.
Lead Product(s): BOLD-100,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: BOLD-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2021
Details:
BOLD-100 consistently reduced viral concentrations in multiple COVID-19 variants, including the highly prevalent B.1.1.7 variant originally identified in the UK.
Lead Product(s): BOLD-100
Therapeutic Area: Infections and Infectious Diseases Product Name: BOLD-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2021
Details:
BOLD-100 is a first-in-class ruthenium-based therapeutic that selectively inhibits stress-induced upregulation of GRP78 and alters the unfolded protein response (UPR), mitigating resistance, survival and proliferation, with additional synergistic direct anti-cancer activity.
Lead Product(s): BOLD-100,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: BOLD-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
Details:
Consistent with prior experiments, BOLD-100 showed low nanomolar IC50 values, a magnitude lower (1/10th) than the IC50 values of Gilead’s remdesivir, the only currently approved therapeutic for COVID-19.
Lead Product(s): BOLD-100
Therapeutic Area: Infections and Infectious Diseases Product Name: BOLD-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020
Details:
Study performed at the Western University generated and subsequently confirmed in vitro data showing nanomolar half maximal inhibitory concentration (IC50) values for BOLD-100 in a cytopathic effect assay using a Wuhan strain of SARS-CoV-2.
Lead Product(s): BOLD-100
Therapeutic Area: Infections and Infectious Diseases Product Name: BOLD-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020